Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults With Refractory Hematologic Malignancies - Concepedia

Concepedia

Publication | Open Access

Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults With Refractory Hematologic Malignancies

DOI Full Paper Access

174

Citations

20

References

2005

Year

Joanne Kurtzberg, T J Ernst, Michael J. Keating, Varsha Gandhi, Jeffrey P. Hodge, David F. Kisor, Joanne Lager, Connie Stephens, Jay M. Levin, Thomas A. Krenitsky,

Journal of Clinical Oncology

Abstract

Nelarabine is a novel nucleoside with significant cytotoxic activity against malignant T cells. DLT is neurologic. Phase II and III trials in patients with T-cell malignancies are encouraged.

References

	Year	Citations

Page 1